|
Study
|
Biomarkers
|
Initial performance reported
|
Performance validation (our cohort)
|
|---|
|
n total (T/C)
|
SN (%)
|
SP (%)
|
AUC
|
n total (T/C)
|
SN (%)
|
SP (%)
|
AUC
|
|---|
|
Hessels et al., 2003 [4]
|
PCA3
|
108 (24/84)
|
67
|
83
|
0.717
|
224 (151/73)
|
49
|
85
|
0.708
|
|
Hessels et al., 2007 [9]
|
PCA3, TMPRSS2:ERG
|
108 (78/30)
|
73
|
52
|
-
|
224 (151/73)
|
48
|
86
|
0.708
|
|
Laxman et al., 2008 [10]
|
PCA3, TMPRSS2:ERG, GOLPH2, SPINK1
|
234 (138/96)
|
66
|
76
|
0.758
|
224 (151/73)
|
72
|
64
|
0.719
|
|
Ouyang et al., 2009 [11]
|
PCA3, AMACAR
|
92 (43/49)
|
81
|
53
|
-
|
224 (151/73)
|
48
|
85
|
0.707
|
|
Rigau et al., 2010 [12]
|
PCA3, PSGR
|
215 (73/142)
|
77
|
60
|
0.73
|
224 (151/73)
|
62
|
71
|
0.708
|
|
Present study, 2015
|
HIST1H2BG, SPP1, ELF3 and PCA3
|
224 (151/73)
|
77
|
83
|
0.763
|
224 (151/73)
|
77
|
83
|
0.763
|
- Abbreviations: T Tumors, C Controls, SN Sensitivity, SP Specificity, AUC Area Under the Curve
